» Articles » PMID: 21316093

Morbidity of Prostate Biopsy After Simplified Versus Complex Preparation Protocols: Assessment of Risk Factors

Overview
Journal Urology
Specialty Urology
Date 2011 Feb 15
PMID 21316093
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine whether prostate biopsy complications were affected by 2 varying prebiospy protocols implemented at our institution. Although transrectal ultrasound (TRUS) guided prostate biopsy is considered generally safe, it is associated with significant complications.

Methods: We retrospectively evaluated a total of 1438 TRUS-guided prostate biopsies between January 2001 and June 2008. In group A, 931 men had only one dose of a quinolone antibiotic immediately before the procedure, and no enema was performed. In group B, 507 men who underwent a prebiopsy enema and were given oral antibiotics starting the day before the procedure for 3 days. We analyzed demographics and biopsy complications between the 2 groups.

Results: The overall complication rates were categorized as infection (2.2%), urine retention (0.8%), hematuria (4.4%), rectal bleeding (1.5%), sepsis (0.2%). There was no significant statistical difference in the incidence of infection or sepsis between the 2 groups (2.7% vs 1.4%, P = .157 and 0.1% vs 0.4%, P = .285 respectively, for group A vs B). Both hematuria and hematospermia were more common in group B (2.5% vs 7.9%, P < .001 and 0.2% vs 2%, P < .001 respectively, for group A vs B). Prostate size was a significant risk for both hematuria (odds ratio = 1.7, 95% confidence interval = 1.2-2.44, P = .003) and acute urinary retention (odds ratio = 4.45, 95% confidence interval = 2.01-9.84, P < .001).

Conclusions: This study demonstrates that a single antibiotic dose before prostate biopsy may be sufficient. In addition, use of prebiopsy enemas is unnecessary to decrease overall complication rates.

Citing Articles

Development and validation of a nomogram model for predicting acute urinary retention after transrectal prostate biopsy.

Wang H, Li S, Wei S, Cao S, Huang X, Hu C Transl Androl Urol. 2025; 14(1):15-26.

PMID: 39974802 PMC: 11833541. DOI: 10.21037/tau-24-399.


Non-infectious complications following transrectal prostate needle biopsy - Outcomes from over 8000 procedures.

Sosenko A, Owens R, Yang A, Alzubaidi A, Guzzo T, Trabulsi E Prostate Int. 2022; 10(3):158-161.

PMID: 36225283 PMC: 9520411. DOI: 10.1016/j.prnil.2022.04.002.


Assessing the accuracy of multiparametric MRI to predict clinically significant prostate cancer in biopsy naïve men across racial/ethnic groups.

Meza J, Babajide R, Saoud R, Sweis J, Abelleira J, Helenowski I BMC Urol. 2022; 22(1):107.

PMID: 35850677 PMC: 9295380. DOI: 10.1186/s12894-022-01066-9.


The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy.

Goldberg H, Mohsin F, Chandrasekar T, Wallis C, Klaassen Z, Ahmad A Can Urol Assoc J. 2021; 16(5):E248-E255.

PMID: 34941486 PMC: 9119600. DOI: 10.5489/cuaj.7464.


Is there any priority between the alpha blockers on voiding functions after transrectal ultrasound guided prostate biopsy?.

Efesoy O, Saylam B, Tek M, Bozlu M, Akbay E Turk J Urol. 2021; 47(2):137-143.

PMID: 33819444 PMC: 8018811. DOI: 10.5152/tud.2021.20509.